Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial
Europace · 2025
DOI: 10.1093/europace/euaf200 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Europace, 2025. Verfasst von Seiko N Doi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, Denmark. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Atrial Fibrillation, Heart Failure, Stroke Volume. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medtronic, St. Jude Medical, TrygFonden.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Atrial fibrillation (AF) is associated with an increased risk of sudden cardiac death. Therefore, the effect of an implantable cardioverter-defibrillator (ICD) may be greater in patients with AF. We examined the long-term effects of primary prevention ICD implantation vs. usual clinical care according to AF status in DANISH. Methods and results Outcomes were analysed according to AF status at baseline (history and/or on enrollment ECG). The primary outcome was all-cause death, and secondary outcomes were cardiovascular and sudden cardiovascular death. Of the 1116 patients with non-ischaemic heart failure with reduced ejection fraction randomized in DANISH, 418 (37.5%) had AF at baseline, of whom 24.2% had paroxysmal AF, 17.0% persistent AF, and 58.9% permanent AF. AF status did not significantly modify the effect of ICD implantation on all-cause death, although there was a suggestion of a greater effect in patients with [hazard ratio (HR) 0.78 (95% CI, 0.59–1.03)] vs. without AF [HR 0.98 (0.75–1.27)] (Pinteraction = 0.15). AF status significantly modified the effect of ICD implantation on cardiovascular death, such that ICD implantation was associated with a lower rate of this outcome in patients with AF [HR 0.67 (0.48–0.94)], but not in those without AF [HR 1.04 (0.76–1.41)] (Pinteraction = 0.04). Although AF status did not significantly modify the effect of ICD implantation on sudden cardiovascular death, there was a suggestion of a greater effect in patients with [HR 0.45 (0.24–0.82)] vs. without AF [HR 0.76 (0.41–1.38)] (Pinteraction = 0.20).
Conclusion
In the DANISH trial, the presence of AF was associated with a greater effect of ICD implantation on cardiovascular death, and although similar trends were observed for all-cause and sudden cardiovascular death, the treatment-by-subgroup interaction was not statistically significant for these outcomes. Registration URL: https://www.clinicaltrials.gov; unique identifier: NCT00542945.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, Denmark.
- Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center, Suita, Japan.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Cardiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
ORCID-Profile: Seiko N Doi, Adelina Yafasova, Jens Jakob Thune, Jens C Nielsen, Niels E Bruun, Lars Videbæk, Hans Eiskjær, Christian Hassager, Jesper H Svendsen, Dan E Høfsten, Steen Pehrson, Lars Køber, Jawad H Butt
Förderung
- Medtronic
- St. Jude Medical
- TrygFonden
- Danish Heart Foundation
- Japan Society for the Promotion of Science
- JSPS
Zitieren
APA
Doi, S. N., Yafasova, A., Thune, J. J., Nielsen, J. C., Bruun, N. E., Videbæk, L., Eiskjær, H., Hassager, C., Svendsen, J. H., Høfsten, D. E., Pehrson, S., Køber, L., & Butt, J. H. (2025). Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial. Europace. https://doi.org/10.1093/europace/euaf200
Vancouver
Doi SN, Yafasova A, Thune JJ, Nielsen JC, Bruun NE, Videbæk L, et al. Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial. Europace. 2025. doi:10.1093/europace/euaf200
BibTeX
@article{Doi2025,
author = {Doi, Seiko N and Yafasova, Adelina and Thune, Jens Jakob and Nielsen, Jens C and Bruun, Niels E and Videbæk, Lars and Eiskjær, Hans and Hassager, Christian and Svendsen, Jesper H and Høfsten, Dan E and Pehrson, Steen and Køber, Lars and Butt, Jawad H},
title = {Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial},
journal = {Europace},
year = {2025},
doi = {10.1093/europace/euaf200}
}
EUVIMED